Market Research Assistance

On the Web
Refine Result

By Date

Last Month
Last 3 Months
Last 6 Months
Last Year
Last 2 Years

By Price

< $1000
$1000-$2500
$2501-$4000
$4001-$5500
$5501-$7500
$7501-$9000
>$9000
Biosimilar

    Biosimilar Market Research Reports

    Titlepublishedprice

    Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan – It’s Time to Welcome Antibody Biosimilars of Foreign Origins Soon

    By MP Advisors
    "......ecause – 1.) it will open antibody biosimilar market in Japan, and 2.) the approval will be based largely from overseas data. ~ ¥200b worth of biologic products is going off patent by 2015 and this value exceeds ~ ¥400b if we include products ......"
    21-Feb-2014$2500

    Global Biosimilars Market 2014-2018

    By Infiniti Research Limited
    "......f biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. TechNavio's report, the Global Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with in......"
    14-Feb-2014$3000

    Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) – Global Forecast to 2018

    By MarketsandMarkets
    "......rket is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and fo......"
    18-Nov-2013$4650

    Therapy Class Overview : Rituximab Biosimilar

    By MP Advisors
    "......s in Europe last year.  This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had ......"
    7-Oct-2013$2000

    The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

    By Kalorama Information
    "......rends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importanc......"
    22-Sep-2013$2995

    Biological and Biosimilars Drug Market in Poland 2013

    By PMR
    "......lnesses for which these drugs are prescribed includes psoriasis, Crohn's disease, colitis, psoriatic and rheumatoid arthritis, ankylosing spondylitis and others. Consequently, the market has expanded recently to encompass new drugs and therapies desi......"
    31-Aug-2013$2660

    Biosimilar Opportunities in an Evolving Market

    By Espicom Limited
    "......l disease and plaque psoriasis. For the two successful applicants, Celltrion and Hospira, this development passes a significant milestone for the whole biosimilar sector as the products are the first monoclonal antibody (mAb) therapies to reach a pos......"
    1-Aug-2013$1495

    Biologics and Biosimilars World Markets

    By TriMark Publications, LLC
    "......iologics (SEBs), biosimilars are to biologics what generics are to branded drugs; they lower healthcare expenditures. This TriMark Publications report describes the emergence of biologics and biosimilars and their potential role in shaping the future......"
    1-Aug-2013$3400

    PharmaSphere: Global Biosimilars Strategy – Regulatory Landscape, Key Drivers, Markets and Trends in 2013

    By GlobalData
    "...... trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as India – providing in-depth analysis of th......"
    27-May-2013$2995

    Therapeutic Class Report Overview – Rituxan Biosimilar

    By MP Advisors
    "......tuximab), Merck and JNJ’s Remicade (infliximab), and Amgen and Pfizer’s Enbrel (etanercept) had WW sales of ~$23b in 2011 and have  patents expiring in EU and ROW in 2013/14.  Biosimilar version of Rituxan was launched by Dr Reddy’s Lab. (DRL......"
    4-Feb-2013$2000
    Live Chat
    Live Chat by Comm100